THE COMMISSION ON CANCER of the American College of Surgeons granted its bi-annual Outstanding Achievement Award to 20 accredited cancer programs throughout the U.S. The awards were based on surveys conducted during the first half of the year.
THE LEUKEMIA & LYMPHOMA SOCIETY received a charitable donation from Bristol-Myers Squibb Company for chronic myeloid leukemia patients who need help paying for PCR testing.
LOPA MISHRA has decided to leave MD Anderson Cancer Center, effective Aug. 31.
Mirati Therapeutics Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced they have entered into an exclusive clinical trial collaboration.
STEPHEN LESSNICK was named director of the Center for Childhood Cancer and Blood Disorders at the Research Institute at Nationwide Children's Hospital.
JINGHUI ZHANG was named as the first chair of the Department of Computational Biology at St. Jude Children's Research Hospital. She will hold the St. Jude Endowed Chair in Bioinformatics.
AstraZeneca and Heptares Therapeutics entered into a licensing agreement under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialize the adenosine A2A receptor antagonist HTL-1071, a small molecule immuno-oncology candidate.
JOHN CUNNINGHAM was appointed chairman of the Department of Pediatrics at the University of Chicago.
The European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products, granted orphan drug designation to synthetic hypericin, the active pharmaceutical ingredient in SGX301, for the treatment of cutaneous T-cell lymphoma, a rare disease and a class of non-Hodgkin's lymphoma.
SITEMAN CANCER CENTER at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis was awarded an “exceptional” rating, the highest possible, by the NCI, based on a rigorous peer review of Siteman's research programs. Siteman is an NCI-designated Comprehensive Cancer Center.
